Ocular Tolerance, Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1.0, 1.5% in 48 Healthy Volunteers
To compare the ocular tolerance, the safety and the ocular pharmacokinetics of 3 concentrations (0.5% - 1.0% - 1.5%) and the vehicle of T1225 after one drop instillation
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||Comparison of the Ocular Tolerance, the Safety and the Ocular Pharmacokinetics After One Drop of Three Different Concentrations of T1225 (0.5% - 1.0% - 1.5%) in 48 Healthy Volunteers|
- Ocular subjective symptoms
- Ocular objective symptoms
- Ocular pharmacokinetic.
- Ocular and systemic adverse events.
|Study Start Date:||March 2002|
|Estimated Study Completion Date:||April 2002|
The aim of the present study was to compare the ocular tolerance, safety and the ocular pharmacokinetics after a single administration of T1225 eye drops (0.5%, 1.0%, or 1.5%) in healthy volunteers.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00357292
|Principal Investigator:||Khalid TABBARA, Professor||The Eye Center, Riyadh (Saudi Arabia)|